Discovery of SAR184841, a potent and long-lasting inhibitor of 11β-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D

https://doi.org/10.1016/j.bmcl.2013.02.018Get rights and content

Abstract

Starting from 11β-HSD1 inhibitors that were active ex vivo but with Cyp 3A4 liability, we obtained a new series of adamantane ureas displaying potent inhibition of both human and rodent 11β-HSD1 enzymes, devoid of Cyp 3A4 interactions, and rationally designed to provide long-lasting inhibition in target tissues. Final optimizations lead to SAR184841 with good oral pharmacokinetic properties showing in vivo activity and improvement of metabolic parameters in a physiopathological model of type 2 diabetes.

References and notes (30)

  • Y. Kotelevtsev et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (1997)
    H. Masuzaki et al.

    Science

    (2001)
  • C. Hale et al.

    Mini-Rev. Med. Chem.

    (2008)
    S.A. Morgan et al.

    Expert Opin. Investig. Drugs

    (2010)
    D. Sun et al.

    Curr. Top. Med. Chem.

    (2011)
  • K.M. Mahar Doan et al.

    J. Pharmacol. Exp. Ther.

    (2002)
  • Receptor binding assays performed by Cerep...
  • J.W. Tomlinson et al.

    Endocr. Rev.

    (2004)
  • R. Thieringer et al.

    Expert Rev. Cardiovasc. Ther.

    (2005)
    M. Wamil et al.

    Drug Discovery Today

    (2007)
  • T. Barf et al.

    J. Med. Chem.

    (2002)
    P. Alberts et al.

    Diabetologia

    (2002)
    V.S.C. Yeh et al.

    Bioorg. Med. Chem. Lett.

    (2006)
    Z.K. Wan et al.

    J. Med. Chem.

    (2009)
    L. Wang et al.

    PLoS ONE

    (2012)
  • O. Paulmyer-Lacroix et al.

    J. Clin. Endocrinol. Metab.

    (2002)
    K. Kannisto et al.

    J. Clin. Endocrinol. Metab.

    (2004)
    E. Rask et al.

    J. Clin. Endocrinol. Metab.

    (2001)
  • S.H. Van Uum et al.

    Semin. Vasc. Med.

    (2004)
  • Y.V. Kotelevtsev et al.

    J. Clin. Invest.

    (1999)
  • T. Barf et al.

    J. Med. Chem.

    (2002)
  • B.G. Bhat et al.

    J. Pharmacol. Exp. Ther.

    (2007)
  • S. Caille et al.

    J. Org. Chem.

    (2009)
  • J.S. Scott et al.

    J. Med. Chem.

    (2012)
  • Cited by (13)

    • Application of carbamyl in structural optimization

      2020, Bioorganic Chemistry
      Citation Excerpt :

      Crystal structure of compound 31 with human 11β-HSD1 (PDB: 4HX5) was also investigated. It showed the carbamyl generated hydrogen bond with the oxygen atom of NADP(H) and another hydrogen bond with Thr124 mediated by one water molecule, which was responsible for the potent biological activity [92]. From hit compound 32 (Fig. 5) showing moderate activity on 11β-HSD1 (IC50 = 390 nM), Lee et al. replaced the cyclohexane to adamantyl fragment and designed several analogues.

    • Progress in 11β-HSD1 inhibitors for the treatment of metabolic diseases: A comprehensive guide to their chemical structure diversity in drug development

      2020, European Journal of Medicinal Chemistry
      Citation Excerpt :

      However, the adamantyl group was thought to be a cause of metabolic liability [83]. To address this problem, additional hydrophilic groups such as an amide, carboxylic acid or hydroxyl group were commonly linked to optimize their physico-chemical properties [77]. Moreover, similar to the adamantyl moiety, hydrophobic groups substituted phenyl or cyclohexane moiety was also commonly observed in 11β-HSD1 inhibitors to form the hydrophobic interaction with 11β-HSD1 [83].

    • Design, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction

      2017, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Given that the 11β-HSD1 active site includes a hydrophobic pocket that can accommodate bulky lipophilic substituents, the introduction of a lipophilic group, such as adamantyl, has proven a successful strategy for the space filling of the cavity. Thus, several adamantyl-containing 11β-HSD1 inhibitors exhibit high affinity and potency and some of them (e.g. AZD8329 and ABT-384) have reached clinical trials (Fig. 1) [26–34]. Although the evaluation of alternative polycyclic hydrocarbons may offer further opportunities for optimizing the space filling of the hydrophobic cavity, the use of other polycyclic substituents featuring different size or shape has only been briefly scrutinized (e.g. AMG-221 and MK-0736) [35,36].

    View all citing articles on Scopus
    View full text